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Abstract
Background: Gabapentin and pregabalin have wide-ranging therapeutic actions, and are structurally related to the
inhibitory neurotransmitter GABA. Gabapentin, pregablin and GABA can all modulate voltage-activated Ca2+ channels.
In this study we have used whole cell patch clamp recording and fura-2 Ca2+ imaging to characterise the actions of
pregabalin on the electrophysiological properties of cultured dorsal root ganglion (DRG) neurones from neonatal rats.
The aims of this study were to determine whether pregabalin and gabapentin had additive inhibitory effects on high
voltage-activated Ca2+ channels, evaluate whether the actions of pregabalin were dependent on GABA receptors and
characterise the actions of pregabalin on voltage-activated potassium currents.
Results: Pregabalin (25 nM – 2.5 µM) inhibited 20–30% of the high voltage-activated Ca2+ current in cultured DRG
neurones. The residual Ca2+ current recorded in the presence of pregabalin was sensitive to the L-type Ca2+ channel
modulator, Bay K8644. Saturating concentrations of gabapentin failed to have additive effects when applied with
pregabalin, indicating that these two compounds act on the same type(s) of voltage-activated Ca2+ channels but the
majority of Ca2+ current was resistant to both drugs. The continual application of GABA, the GABAB receptor antagonist
CGP52432, or intracellular photorelease of GTP-γ-S had no effect on pregabalin-induced inhibition of Ca2+ currents.
Although clear inhibition of Ca2+ influx was produced by pregabalin in a population of small neurones, a significant
population of larger neurones showed enhanced Ca2+ influx in response to pregabalin. The enhanced Ca2+ influx evoked
by pregabalin was mimicked by partial block of K+ conductances with tetraethylammonium.
Pregabalin produced biphasic effects on voltage-activated K+ currents, the inhibitory effect of pregabalin was prevented
with apamin. The delayed enhancement of K+ currents was attenuated by pertussis toxin and by intracellular application
of a (Rp)-analogue of cAMP.
Conclusions: Pregabalin reduces excitatory properties of cultured DRG neurones by modulating voltage-activated Ca2+
and K+ channels. The pharmacological activity of pregabalin is similar but not identical to that of gabapentin. The actions
of pregabalin may involve both extracellular and intracellular drug target sites and modulation of a variety of neuronal
conductances, by direct interactions, and through intracellular signalling involving protein kinase A.
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Background
Gabapentin (Neurotonin®) and pregabalin (S(+)-3-iso-
butyl GABA) were both originally designed as GABA
mimetics (Figure 1A), with the intention that they would
be able to cross the blood-brain barrier and interact with
GABAergic systems and enhance GABA mediated inhibi-
tion. Although gabapentin appears to have diverse thera-
peutic utility in the treatment of pain disorders [1],
psychiatric illnesses [2] and epilepsy [3], there is contro-
versy regarding its molecular mechanisms of action.
Whether the actions of gabapentin and pregabalin are
mediated through GABAergic mechanisms or GABA
receptors remains particularly contentious [4-6]. How-
ever, high affinity binding sites for gabapentin and prega-
balin on distinct α2δ subunits of voltage-activated calcium
channels have been identified and characterised [7]. For
this reason voltage-activated Ca2+ channels remain pri-
mary candidate sites of action for these novel anticonvul-
sant and antihyperalgesic drugs. Functional data from
studies on gabapentin and pregabalin also support this
contention. Specifically, both gabapentin and pregabalin
inhibited hyperalgesia [8,9], attenuated evoked Ca2+
influx into brain slices and reduced evoked transmitter
release [10]. Additionally, gabapentin and pregabalin
inhibited multiple firing of action potentials evoked by
300 ms depolarising current commands in cultured sen-
sory DRG neurones [5].
Our previous studies have focused on the inhibitory
effects of gabapentin (0.25–25 µM) on whole cell voltage-
activated Ca2+ currents and K+ stimulated Ca2+ entry meas-
ured with fura-2. The cellular model systems used were
primary cultures of dorsal root ganglion (DRG) neurones
from 1–4 day old rats and differentiated F-11 cells
(embryonic rat DRG × neuroblastoma hybrid cell line)
[11,12].
In this present study the effects of pregabalin and gabap-
entin on the electrophysiological properties of cultured
neonatal rat DRG neurones were measured with particular
reference to Ca2+  entry through high voltage-activated
channels and enhancement of K+ conductances. We had
two specific aims for this project. The first was to deter-
mine whether gabapentin and pregabalin have the same
mechanisms of action, by examining whether saturating
concentrations of gabapentin and pregabalin act in an
additive manner to attenuate Ca2+ influx. The second aim
was to further evaluate GABA receptors as target sites for
these drugs in sensory neurones. This latter element to the
study was conducted because it has been proposed that
specific GABAB receptors with a gb1a-gb2 heterodimer
composition are the sites of agonist activity of gabapentin.
These specific receptors can be coupled to an inwardly rec-
tifying K+ channel and / or voltage-activated Ca2+ channels
to dampen neuronal electrical excitability [13-15]. How-
ever, in certain situations gabapentin and the GABAB
receptor agonist, baclofen, have different actions. Weaver
mutant mice (wv/wv) are insensitive to both gabapentin
and baclofen, however in control littermates, Weaver con-
trol mice (+/+, wv/+), only baclofen evoked a K+ current
[16].
Results and discussion
Actions of pregabalin on voltage-activated calcium 
currents
The firing of multiple action potentials in response to a
sustained depolarising current command is a property of
a sub-population (under 20 %) of cultured DRG neu-
rones. Application for 3 minutes, of either pregabalin
(PGB; 2.5 µM) or gabapentin (GBP; 2.5 µM) reduced the
frequency of action potential spikes evoked by 300 ms
depolarising current step commands applied every 30 s
[5]. Gabapentin attenuated repetitive action potential fir-
ing as measured by a reduction in the mean number of
evoked action potentials during 300 ms depolarisations
from 7 to 2 (n = 3, p < 0.01). Pregabalin (2.5 µM) reversi-
bly reduced the number of action potentials during 300
ms depolarisations from 8 to 3 (n = 5, p < 0.01). However,
pregabalin and gabapentin did not significantly alter the
properties (amplitude, duration & threshold) of single
action potentials evoked by 5 ms depolarising current
commands.
Consistent with our previous work [11,12], whole cell
voltage-activated Ca2+ currents (ICa) recorded from DRG
neurones were reversibly attenuated (22 ± 11%; n = 7) by
2.5 µM gabapentin. Similarly, 3 minutes application of
pregabalin (25 nM – 2.5 µM; Figure 1B &1C; table 1)
inhibited the mean Ca2+ current amplitude, measured at
the peak of the inward current, and at the end of a 100 ms
voltage step command to 0 mV. The inhibitory actions of
pregabalin were not accompanied by any shift in the volt-
age-dependence of activation for ICa or by any change in
holding or leak currents. At least partial recovery of ICa was
observed 5 minutes after removal of the pregabalin-con-
taining perfusion pipette (Figure 1B &1C). A very low con-
centration of pregabalin (0.25 nM) failed to produce
significant inhibition of ICa. However, no clear dose-
dependent relationship was established for the inhibitory
actions of pregabalin, and a major part of the voltage-acti-
vated Ca2+ current was insensitive to the drug. It was also
apparent that there was considerable variability in the sen-
sitivity of the DRG neurones to any given dose of pregab-
alin. Some neurones did not respond to 2.5 µM
pregabalin while in a few neurones this same concentra-
tion produced 60 % inhibition of ICa (Figure 1D).
Distinct voltage-activated Ca2+ channels, defined by their
alpha 1 subunit, have been suggested to be selective target
sites for gabapentin and related drugs like pregabalin.BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
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Pregabalin inhibits Ca2+ currents Figure 1
Pregabalin inhibits Ca2+ currents. A) Structure of GABA (γ-aminobutyric acid), gabapentin (1-(aminoethyl)cyclohexane acetic 
acid) and pregabalin (S(+)-3-isobutyl GABA). B & C) Traces of high voltage-activated Ca2+ currents evoked from a holding 
potential of -90 mV by a depolarising step command to 0 mV showing inhibition by pregabalin (2.5 µM). B) Shows that pressure 
ejection of choline chloride extracellular solution does not induce inhibition of the Ca2+ current but in the same neurone pre-
gabalin does produce a response. Traces show a control Ca2+ current (Ctrl), the current unaffected by application of choline 
chloride recording solution (ChCl), inhibition of current by 3 minutes application of pregabalin (PGB) and the current at 5 min-
utes recovery (Rec). C) Traces show a control Ca2+ current (Ctrl), the inhibition of current after 3 minutes application of pre-
gabalin (PGB) and full recovery of the current 5 minutes after removal of the drug pipette (Rec). D) Graph showing the 
distribution of inhibitory responses produced by 0.025 – 2.5 µM pregabalin. Each symbol represents a result from a different 
experiment.
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With this in mind, the 1,4-dihydropyridine L-type Ca2+
channel agonist Bay K8644 was used to determine
whether pregabalin was inhibiting L-type channels. Previ-
ously, we found that in the continual presence of gabap-
entin, Bay K8644 enhanced ICa [12]. In this present study
similar results were obtained. After inhibiting part of the
current with pregabalin (2.5 µM), Bay K8644 (1 µM) was
applied with pregabalin and the enhanced ICa was meas-
ured at its peak and at the end of a 100 ms voltage step
command to 0 mV (Figure 2). The percentage increases in
current seen with Bay K8644 in the presence of either
gabapentin or pregabalin were slightly less than those
seen under control conditions in cultured DRG neurones
[17]. This is consistent with some L-type Ca2+ current
modulation by pregabalin and gabapentin in DRG neu-
rones. Taken together these data suggest that neither
gabapentin nor pregabalin are selectively inhibiting L-
type ICa in DRG neurones. This contrasts with the effects of
gabapentin on cortical pyramidal neurones where inhibi-
tion of L-type Ca2+ channels appears to be the predomi-
nant mechanism of action [18].
Actions of pregabalin on calcium influx through voltage-
activated channels, measured using fura-2 imaging
Given the variable and rather modest but reversible inhib-
itory actions of pregabalin on ICa we tested the actions of
pregabalin on K+-evoked Ca2+ influx using fura-2 imaging.
An extracellular solution containing 30 mM K+ was used
to depolarise the DRG neurones and activate three con-
sistent Ca2+ transients [11,12]. Pregabalin (2.5 µM) was
applied during the second K+-evoked depolarisation and
it produced a mixture of reversible effects on the Ca2+ tran-
sients. In 4 of 24 neurones the Ca2+ flux was decreased by
54 ± 13 % (p<0.05) but in 20 neurones from the same cul-
tures pregabalin evoked a mean increase in Ca2+ flux to
185 ± 20 % (p<0.05) of the control. Raising the pregabalin
concentration to 25 µM increased the proportion of
inhibitory responses (n = 21 out of 49 neurones) but
enhancement of Ca2+ transients was still observed in the
remaining 28 neurones (Figure 3). However, 250 µM pre-
gabalin caused an increase in K+-evoked Ca2+ influx in all
neurones studied (n = 31). Although in some cells good
recovery from pregabalin actions was observed (figure 3B)
the inhibitory effect was often not associated with
recovery. This may reflect long lasting effects of pregaba-
lin. Run-down in some cells can not be completely ruled
out but under control conditions the mean level of run-
down of three K+-evoked Ca2+ transients was only 8.4 ±
1.5 % (n = 39). Similarly, the mean control level of
increase in K+-evoked Ca2+ transients was only 7.2 ± 1.3 %
(n = 35).
To investigate the different responses to pregabalin, the
sizes of cell somas were measured and compared.
Although there is overlap, figure 4 shows that enhance-
ment of K+-evoked Ca2+  transients by pregabalin was
mainly seen in neurones with larger cell somas and that in
smaller neurones pregabalin produced inhibitory effects.
Ca2+-dependent conductances of DRG neurones are sensi-
tive to ryanodine and Ca2+-induced Ca2+ release has been
reported in these neurones. Modulation of either Ca2+-
induced Ca2+ release and / or Ca2+ homeostatic mecha-
nisms might provide a mechanism by which pregabalin
enhanced Ca2+ transients in neurones with intermediate
and large sized cell somas. This was investigated in two
ways. Firstly, the actions of pregabalin on caffeine-evoked
Ca2+  transients were evaluated in nominally Ca2+-free
extracellular conditions (NaCl-based solution with no
added CaCl2). Single caffeine (1 mM) responses were
obtained from DRG neurones in either the absence or
presence of 25 µM pregabalin. No differences in either
amplitudes or durations of Ca2+  transients were seen
when 8 control caffeine responses were compared with 4
caffeine responses obtained in the presence of pregabalin
(Figure 5A,5B). The second approach was to explore a
possible role of Na+ / Ca2+ exchange by bathing cells in
choline chloride-based medium containing only 1 mM
Na+. Under these conditions the contribution of the Na+ /
Ca2+ exchanger to handling of intracellular Ca2+ loads will
be minimal. In choline chloride-based medium pregaba-
lin produced both enhancement and inhibition of total
Ca2+ flux in 7 and 3 neurones respectively. Enhancement
in Ca2+  flux by pregabalin under these experimental
Table 1: Inhibitory actions of pregabalin on voltage-activated calcium currents.
Peak control current amplitude 
(nA)
Pregabalin Concentration (µM) Peak current in the presence of 
pregabalin (nA)
Percentage inhibition and n value
-1.52 ± 0.13 0.025 -0.98 ± 0.12 ** 31 ± 4 % (n = 8)
-1.2 ± 0.14 0.25 -0.93 ± 0.18 * 22 ± 9 % (n = 6)
-1.19 ± 0.11 2.5 -0.94 ± 0.09*** 21 ± 3 % (n = 26)
***P < 0.001; **P < 0.01 and *P < 0.05. Each value is given ± S.E.M. Data shows inhibition but a lack of dose-dependent actions on ICa of a wide range 
of pregabalin concentrations. Although varied responses were observed it was clear that a major component of ICa was resistant to inhibition by 
pregabalin.BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
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Bay K8644 enhanced pregabalin-insensitive current suggesting that L-type Ca2+ channels are still available for modulation by the  1,4-dihydropyridine agonist Figure 2
Bay K8644 enhanced pregabalin-insensitive current suggesting that L-type Ca2+ channels are still available for modulation by the 
1,4-dihydropyridine agonist. A) Bar chart shows data for mean calcium current amplitudes measured at the peak of the inward 
current (open bars) and at the end of a 100 ms voltage step command to 0 mV (solid bars, n = 6). Data under control condi-
tion (Con) in the presence of 2.5 µM pregabalin (PGB) and in the presence of both pregabalin (2.5 µM) and Bay K8644 (1 µM) 
are shown. B) The inset traces show voltage and Ca2+ current records under control conditions, inhibition in the presence of 
2.5 µM pregabalin (PGB) and enhancement of the Ca2+ current during continued application of pregabalin with Bay K8644 
present (Bay K & PGB). C) Shows the current inhibited by pregabalin, (obtained by subtracting the net current recorded in the 
presence of pregabalin from the net control current). D) Shows the additional current produced by Bay K8644, (obtained by 
subtracting the net current recorded in the presence of pregabalin from the net current recorded in the presence of both pre-
gabalin and Bay K8644).
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Pregabalin produced mixed actions on Ca2+ influx evoked by 30 mM K+ Figure 3
Pregabalin produced mixed actions on Ca2+ influx evoked by 30 mM K+. A) Bar chart showing inhibition of Ca2+ influx by pre-
gabalin (25 µM). Data for the total Ca2+ fluxes was normalised with respect to the first control response to K+ (Ctrl). The sec-
ond and third responses were obtained in the presence of pregabalin (PGB) and after washing away the pregabalin (Rec). B) 
Record of K+-evoked Ca2+ transients showing partially reversible inhibition produced by 25 µM pregabalin (PGB). The period 
of stimulation is shown with open bars and PGB application with the filled bar. C) Bar chart showing enhancement of Ca2+ 
influx by pregabalin (25 µM). Data for the total Ca2+ fluxes were normalised with respect to the first control response to K+ 
(Ctrl). The second and third responses were obtained in the presence of pregabalin (PGB) and after washing away the pregab-
alin (Rec). D) Record of K+-evoked Ca2+ transients showing reversible enhancement produced by 25 µM pregabalin (PGB).
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conditions, suggest that inhibition of Na+ / Ca2+ exchange
is not the main mechanism by which pregabalin enhances
K+-evoked Ca2+ flux (Figure 5C). However, detailed analy-
sis was made difficult by poor recovery of even the first
Ca2+ transient evoked in low extracellular Na+ which does
suggest that Na+ / Ca2+ exchange is an important homeo-
static mechanism in DRG neurones. In conclusion these
results indicate that modulation of Ca2+-induced Ca2+
Different responses to pregabalin were observed in different populations of cultured DRG neurones Figure 4
Different responses to pregabalin were observed in different populations of cultured DRG neurones. Bar chart showing the 
distribution of neurones with different cell soma areas and the response to pregabalin. The distributions for intermediate and 
larger neurones where pregabalin (25 µM) increased K+-evoked Ca2+ influx are shown in black bars. The distributions for small 
and some intermediate neurones where pregabalin (25 µM) attenuated K+-evoked Ca2+ influx are shown in open bars.
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Pregabalin does not appear to modulate caffeine-evoked Ca2+ release or Ca2+ homeostatic mechanisms Figure 5
Pregabalin does not appear to modulate caffeine-evoked Ca2+ release or Ca2+ homeostatic mechanisms. A & B) Show example 
records of Ca2+ transient evoked by caffeine (1 mM) applied to DRG neurones bathed in nominally Ca2+-free medium and 
measured using fura-2. Under these conditions the Ca2+ transients are only due to mobilisation of Ca2+ from intracellular 
stores. A) Illustrates a control caffeine response and B) shows a similar response to caffeine recorded in the presence of 25 µM 
pregabalin (PGB). C) Example trace showing an increase in K+-evoked Ca2+ flux by 25 µM pregabalin (PGB) in a DRG neurone 
bathed with choline chloride-based extracellular medium. The periods of stimulation with 30 mM KCl are shown with open 
bars and pregabalin application is shown with a filled bar. D) Example trace showing an increase in K+-evoked Ca2+ flux induced 
by 5 mM TEA in a DRG neurone bathed with standard NaCl-based extracellular medium. The periods of stimulation with 30 
mM KCl are shown with open bars and TEA application is shown with a filled bar.
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release and Ca2+ homeostatic mechanisms do not account
for pregabalin-induced enhancement of K+-evoked Ca2+
flux in a population of DRG neurones.
Inhibitory modulation of potassium conductances could
result in increased K+-evoked Ca2+ transients. To test this
alternative mechanism, a relatively low concentration, 5
mM, of tetraethylammonium (TEA) was applied with
NaCl-based extracellular medium and DRG neurones
were stimulated with 30 mM KCl. Attenuation of potas-
sium conductances by TEA markedly increased the K+-
evoked Ca2+ flux in all eight DRG neurones studied, mim-
icking in part the action of pregabalin (Figure 5D).
Do pregabalin and gabapentin have additive effects on 
cultured dorsal root ganglion neurones?
Pregabalin and gabapentin have related chemical struc-
tures and appear to have similar but usually modest inhib-
itory effects on Ca2+  currents. Both pregabalin and
gabapentin at a concentration of 2.5 µM produced a max-
imum level of current inhibition. Simultaneous applica-
tion of pregabalin (2.5 µM) and gabapentin (2.5 µM)
produced modest but significant inhibition of ICa at the
peak of the current and at the end of the stimulus (Figure
6A). However, the percentage inhibition of ICa produced
was not significantly different for 2.5 µM gabapentin
alone (22 ± 11%; n = 7), 2.5 µM pregabalin alone (21 ±
3%; n = 26) and 2.5 µM gabapentin and 2.5 µM pregaba-
lin applied together (19 ± 2%; n = 9).
In spite of the added complexity of mixed responses with
pregabalin, experiments were carried out using fura-2 to
measure K+ evoked Ca2+ flux and the effects of both lig-
ands. Our previous experiments with gabapentin (25 µM)
had only identified inhibitory effects using this experi-
mental approach [11,12]. Simultaneous application of
pregabalin and gabapentin (both at 25 µM) reversibly
reduced the K+ evoked Ca2+ influx (Figure 6B &6C). Prega-
balin (25 µM) and gabapentin (25 µM) together reduced
the total Ca2+ flux to 75 ± 5 % (n = 14) of the control
response to 30 mM K+. Consistent with the electrophysio-
logical experiments, this level of inhibition was similar to
the inhibitory effects of pregabalin and gabapentin
applied separately.
The electrophysiological and fura-2 Ca2+ imaging data
show that no additive inhibitory effects were found
during simultaneous application of saturating concentra-
tions of gabapentin and pregabalin. The data therefore
support the contention that both drugs have a closely
related or a common site of inhibitory action. The data
also indicate that in the modulation of Ca2+ channels
these drugs do not act in an additive manner even though
a substantial proportion of current is resistant to both
drugs. It should be emphasized however that pregabalin
can reversibly enhance K+-evoked Ca2+ transients, an effect
not seen with gabapentin. Therefore there may be other
additional actions of pregabalin that can be identified in
Ca2+ imaging experiments when all membrane conduct-
ances are intact.
Does GABA receptor modulation alter responses to 
pregabalin in cultured dorsal root ganglion neurones?
In this section of the study two strategies were used to
evaluate the possible roles of GABA receptors in pregaba-
lin responses in cultured DRG neurones. Firstly, pregaba-
lin actions were studied in the presence of a saturating
concentration of GABA; this initially activated all types of
GABA receptor and then caused desensitization of these
receptors. Secondly, the effect of a potent and selective
GABAB receptor antagonist, CGP52432 [19] on pregaba-
lin responses was evaluated. GABA (100 µM) evoked
inward currents in a sub-population of cultured DRG neu-
rones and induced a transient rise in intracellular Ca2+ in
18 of 41 DRG neurones studied (Figure 7A &7B). The
inward currents were due to the activation of GABAA
receptor Cl- channels; with the equilibrium potential for
Cl- under our recording conditions being close to 0 mV
the chloride conductance results in an inward current.
Although in vivo the equilibrium potential for Cl- in DRG
neurones is variable, it is predicted to be between -40 mV
and -20 mV because of Cl- loading into the intracellular
environment (for review see [20]). Therefore GABAA
receptor Cl-  channel activation can produce a
depolarisation of the resting membrane potential. Our
data indicated that the GABA-evoked depolarisation was
sufficient to result in voltage-activated Ca2+ channel activ-
ity and produce a transient rise in intracellular Ca2+. In
both neurones that responded to GABA and those that did
not, subsequent application of pregabalin, produced
either enhancement or inhibition of K+-evoked Ca2+
influx (Figure 7A,7B,7C &7D; Table 2). These responses to
pregabalin in the presence of GABA were no different in
character to the pregabalin responses obtained in the
absence of GABA. In neurones that showed a Ca2+ tran-
sient in response to a GABA-evoked depolarisation, there
was an apparent increase (to 83%) in the proportion of
neurones that were inhibited by pregabalin. It is not clear
why this is but it may reflect the sensitivity of Ca2+
transients evoked in DRG neurones, which can only be
evoked consistently in most DRG neurones by three depo-
larising stimuli. Thus the GABA-evoked responses may
influence Ca2+ homeostatic mechanisms and subsequent
stimulated Ca2+ entry. However, the critical observation
from these experiments is that GABA receptor desensitisa-
tion does not prevent either Ca2+ transient enhancement
or inhibitory actions of pregabalin in neurones that were
sensitive or insensitive to GABA.BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
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Pregabalin and gabapentin do not have additive actions on cultured DRG neurones Figure 6
Pregabalin and gabapentin do not have additive actions on cultured DRG neurones. A) Bar chart showing the mean Ca2+ cur-
rent amplitude recorded at the peak of the inward current (Peak) and end of a 100 ms voltage step command (End). Data is 
shown for measurements made under control conditions (Control), after 3 to 5 minutes application of both pregabalin (2.5 
µM) and gabapentin (2.5 µM) (PGB + GBP) and after 5 minutes recovery (Recovery). B) Bar chart showing normalised data 
from Ca2+ imaging experiments in which simultaneous application of both pregabalin (25 µM) and gabapentin (25 µM) (PGB & 
GBP) reversibly attenuated the total Ca2+ flux. C) Record of K+-evoked Ca2+ transients, showing the reversible inhibition pro-
duced by 25 µM pregabalin and 25 µM gabapentin (PGB + GBP, filled bar).
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Activation and subsequent desensitisation of GABA receptors fails to prevent the modulation of voltage-activated Ca2+ chan- nels in cultured DRG neurones by pregabalin Figure 7
Activation and subsequent desensitisation of GABA receptors fails to prevent the modulation of voltage-activated Ca2+ chan-
nels in cultured DRG neurones by pregabalin. A) Bar chart showing data obtained from neurones that responded to GABA 
(100 µM). All data are normalised with respect to the first Ca2+ transient evoked by 30 mM KCl. Open bars show the relative 
responses to 100 µM GABA in cells (n = 3) where 25 µM pregabalin enhanced the Ca2+ flux. Filled bars show responses in cells 
(n = 15) where 25 µM pregabalin inhibited the Ca2+ flux. Data are shown for GABA responses (GABA), K+-evoked Ca2+ tran-
sients under control conditions with GABA present (Ctrl), K+ evoked Ca2+ transients in the presence of GABA and 25 µM pre-
gabalin (PGB) and on recovery in the continued presence of GABA (Rec). B) An example trace, showing a response to 100 µM 
GABA and Ca2+ transients evoked by K+ in the presence and absence 25 µM pregabalin. The long open bar shows the period of 
GABA application, the short open bars show K+ stimulation and the filled bar the period of pregabalin application. C) Bar chart 
showing data obtained from neurones that did not responded to GABA (100 µM) but were continually bathed with GABA for 
the duration of the experiment. All data are normalised with respect to the first Ca2+ transient evoked by 30 mM KCl. Data are 
shown for K+-evoked Ca2+ transients under control conditions with GABA present (Ctrl), increased (n = 10; open bars) and 
decreased (n = 13; filled bars) K+-evoked Ca2+ transients in the presence of GABA and 25 µM pregabalin (PGB) and on recov-
ery (Rec). D) An example trace, showing no response to 100 µM GABA but responses to K+ in the presence and absence of 25 
µM pregabalin. The long open bar shows the period of GABA application, the short open bars show K+ stimulation and the 
filled bar the period of pregabalin application.
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The possibility of pregabalin-evoked inhibition of ICa tak-
ing place through activation of G-protein coupled GABAB
receptors, was then assessed. CGP52432 (10 µM) when
applied alone had no effect on ICa. In the presence of the
GABAB receptor antagonist CGP52432 (10 µM), pregaba-
lin (2.5 µM) evoked a 27 ± 3 % (n = 9) inhibition of the
voltage-activated Ca2+ current and complete recovery was
observed 5 minutes after removal of the drug-containing
pipette (Figure 8A). In Ca2+ imaging experiments 10 µM
CGP52432 had no effect on the responses to 25 µM pre-
gabalin. In the presence of CGP52432, 4 out of 16 neu-
rones showed enhanced K+-evoked Ca2+ influx (to 161 ±
24 % (n = 4) of control) in response to pregabalin and 12
neurones showed inhibition of Ca2+ influx (64 ± 8 % (n =
12) of control) in response to pregabalin (Figure 8B &8C).
Is there a role for G-proteins or G-protein coupled 
receptors in the responses to pregabalin in cultured dorsal 
root ganglion neurones?
Previously, we found that the actions of gabapentin on ICa
were attenuated by pre-treating DRG neurones with per-
tussis toxin, an effect that did not appear to involve
metabotropic GABAB receptors [12]. In this study several
different approaches were taken to examine the influence
of receptor and G-protein function in pregabalin actions.
Firstly, the effects of a novel thiadiazole compound, SCH-
202676, which inhibits ligand binding to a variety of G-
protein coupled receptors (opioid, adrenergic, muscarinic
and dopaminergic) were investigated. The selective and
reversible action of SCH-202676 appears to involve allos-
teric modulation of both agonist and antagonist binding
to G-protein coupled receptors [21]. Secondly, the
potential influences of intracellular flash photolysis of
caged GTP-γ-S and subsequent G-protein activation on
pregabalin responses were also examined.
SCH-202676 (10 µM) was applied to the intracellular
environment via the patch pipette solution. After 5 min-
utes equilibration the whole cell Ca2+ current had a mean
amplitude of -0.54 ± 0.08 nA (n= 7). During this period
there was a clear reduction in the inward current, although
a steady state current level was reached. However, subse-
quent application of pregabalin (2.5 µM) resulted in a fur-
ther significant reduction in Ca2+ current amplitude to -
0.43 ± 0.07 nA (n = 7, p<0.05). This represents a mean
inhibition of 22 ± 5 % by pregabalin, a value very similar
to the percentage inhibition produced by pregabalin in
the absence of SCH-202676 (21 ± 3%). Therefore SCH-
202676 had no effect on the pregabalin responses, indi-
cating that pregabalin was not acting through an SCH-
202676-sensitive G-protein coupled receptor (data not
shown). Preliminary Ca2+ imaging experiments were also
conducted to determine whether extracellular SCH-
202676 (10 µM, continually applied throughout the
experiment) altered the effects of pregabalin (2.5 µM) on
K+-evoked Ca2+ transients. Under these experimental con-
ditions pregabalin was found to markedly enhance or
inhibit K+-evoked Ca2+ transients (data not shown). This
data again suggests that pregabalin was not acting through
mechanisms that were sensitive to SCH-202676.
Caged GTP-γ-S (100 µM) was applied to the intracellular
environment via the patch pipette solution and after
entering the whole cell recording configuration DRG neu-
rones were left for 5 minutes to equilibrate. Once a stable
control Ca2+ current was obtained, three 200 V flashes of
intense near UV light were applied to the neurone to
achieve intracellular flash photolysis of the caged GTP-γ-S.
We estimate that approximately 15 µM GTP-γ-S was pho-
toreleased by the three flashes. As previously observed
intracellular flash photolysis of caged GTP-γ-S reduced the
amplitude and slowed the activation of ICa  [22]. The
effects of photoreleased GTP-γ-S were attenuated by
applying a large depolarising pre-pulse [23], which is con-
sistent with voltage-dependent G-protein modulation of
Ca2+ channels (Figure 9A). No recovery from photore-
leased GTP-γ-S was observed during the period of the
experiment. GTP-γ-S and pregabalin (2.5 µM) had
Table 2: Actions of pregabalin (25 µM) on K+-evoked Ca2+influx in the continual presence or absence of 100 µM GABA.
GABA sensitivity Mean percentage of control Ca2+ 
influx
Number of neurones Proportion of Neurones
Responders 110 ± 2 % 3 of 18 17 %
Responders 77 ± 2 % 15 of 18 83 %
Non-responders 121 ± 4 % 10 of 23 43 %
Non-responders 81 ± 3 % 13 of 23 57 %
Control 169 ± 24 % 28 of 49 57 %
Control 85 ± 2 % 21 of 49 43 %
Responders were those neurones in which GABA evoked a transient rise in intracellular Ca2+. Non-responder showed no change in fura-2 
fluorescence ratio in response to GABA. Controls where neurones that pregabalin was applied to without GABA being present. The amplitudes of 
the GABA responses did not vary with the inhibitory or enhancing responses to pregabalin.BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
Page 13 of 26
(page number not for citation purposes)
additive inhibitory effects on ICa. These additive actions of
GTP-γ-S and pregabalin were apparent regardless of the
order of application. One set of experiments was per-
formed in which GTP-γ-S was photoreleased in the intrac-
ellular environment and then after stabilisation of the
response pregabalin was applied (Figure 9B). In another
set of experiments pregabalin was applied first and after
equilibration GTP-γ-S was photoreleased in the continual
presence of pregabalin (Figure 9C). When pregabalin (2.5
µM) was applied first it produced a mean inhibition in ICa
by 25 ± 5 % (n = 4), when applied after photorelease of
GTP-γ-S, pregabalin produced a 20 ± 10 % (n = 5) inhibi-
tion of ICa.
Actions of pregabalin on voltage-activated potassium 
currents
It was clear from the Ca2+ imaging experiments that not all
the cellular actions of pregabalin could be explained by
the inhibition of voltage-activated Ca2+ channels because
both inhibition and enhancement in K+ evoked Ca2+ flux
was observed. To investigate the actions of pregabalin fur-
ther, its' effects on voltage-activated K+ currents in DRG
The GABAB receptor antagonist CGP52432 had no effect on the actions of pregabalin Figure 8
The GABAB receptor antagonist CGP52432 had no effect on the actions of pregabalin. A) Bar chart showing the inhibitory 
effects of 2.5 µM pregabalin in the presence of 10 µM CGP52432 (PGB & CGP) on Ca2+ current amplitude measured at the 
peak inward current (Peak) and at the end of a 100 ms voltage step command to 0 mV (End). The inset traces show the inhibi-
tion of the Ca2+ current produced by 3 minutes application of pregabalin and CGP52432 (PGB + CGP) and partial recovery 5 
minutes after removal of the drug perfusion pipette. B & C) Show example records of 25 µM pregabalin in the presence of 10 
µM CGP52432 (PGB + CGP) modulating Ca2+ flux evoked by 30 mM KCl. The open bars show the period of stimulation with 
K+ and the filled bar the application of pregabalin in the presence of CGP52432 (PGB +CGP).
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Intracellular photorelease of GTP-γ-S did not alter the sensitivity of DRG neurones to pregabalin Figure 9
Intracellular photorelease of GTP-γ-S did not alter the sensitivity of DRG neurones to pregabalin. A) Traces showing a Ca2+ 
current attenuated and slowed by intracellular flash photolysis of caged GTP-γ-S (GTP-γ-S) and a Ca2+ current showing voltage-
dependent partial recovery of GTP-γ-S-evoked inhibition (GTP-γ-S + PP {pre-pulse to +120 mV}). B) Bar chart showing control 
(Ctrl) data, the inhibitory effects of both intracellular photorelease of GTP-γ-S (GTP-γ-S) and subsequent application of 2.5 µM 
pregabalin (GTP-γ-S & PGB) on the mean peak Ca2+ current amplitude. Inset records show individual Ca2+ currents recorded 
under control conditions, after intracellular photorelease of GTP-γ-S (GTP-γ-S) and after subsequent extracellular application 
of pregabalin for 3 minutes (GTP-γ-S + PGB). C) Bar chart showing control (Ctrl) data, the inhibitory effects of both 3 minutes 
extracellular application of 2.5 µM pregabalin (PGB) and subsequent intracellular photorelease of GTP-γ-S in the continued 
presence of pregabalin (PGB & GTP-γ-S) on the mean peak Ca2+ current amplitude. Inset records show individual Ca2+ currents 
recorded under control conditions, after application of pregabalin for 3 minutes (PGB) and after intracellular photorelease of 
GTP-γ-S (PGB & GTP-γ-S). None of the currents in this figure have been leak subtracted. However, neither pregabalin nor 
GTP-γ-S altered the leak current.
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neurones were studied. Previously, Stefani and colleagues
found that gabapentin modulated neuronal steady state
non-inactivating K+ currents [18].
Three minutes application of pregabalin (2.5 µM) had no
significant effect on the voltage-activated K+ current acti-
vated from a holding potential of -90 mV by a 100 ms
voltage step command to 0 mV (Figure 10A). However,
raising the pregabalin concentration to 250 µM resulted in
significant modulation of K+ currents in DRG neurones.
Pregabalin (250 µM) applied for 3 to 5 minutes produced
an enhanced K+ current in 11 out of 21 neurones but a
modest inhibition of the outward current in 10 out of 21
neurones (Figure 10B and 10C). DRG neurones are a het-
erogenous population of neurones and there is evidence
that they express at least 6 diverse voltage-activated K+
channels and that this expression is in part determined by
the type of DRG neurone [24]. To distinguish between the
two responses experiments were carried out on DRG neu-
rones held at -30 mV to inactivate a proportion of the out-
ward current. Under these conditions pregabalin
inhibited the outward current in 9 out of 11 DRG neu-
rones but still produced enhancement in 2 neurones. The
level of inhibition increased at a holding potential of -30
mV to 30 ± 7% (n = 9) compared to 15 ± 4 % (n = 10) at
-90 mV, (data not shown).
Interestingly, in apparent contrast to pregabalin, 250 µM
gabapentin was initially only found to inhibit K+ currents
in DRG neurones (Figure 11A,11B). However, when stud-
ies into long-term (10–15 minutes) actions of gabapentin
were investigated slowly developing outward current
enhancement was identified. So similar to actions of pre-
gabalin, biphasic responses to gabapentin were found
with initial inhibition of K+ currents and then a delayed
enhancement of the outward current (Figure 11C), [5].
Long-term modulation of K+ current by pregabalin was
then investigated. Dramatic increases in outward current
were observed after a delay. This effect of pregabalin
persisted even as pregabalin was removed from the
extracellular environment, which may implicate a meta-
bolic or intracellular signalling event in this response. The
mean K+ current amplitude at +40 mV increased from 3.37
± 0.73 nA to 7.56 ± 1.10 nA (n = 11; p<0.01) 15 minutes
after perfusion of 250 µM pregabalin. Figures 12A and
12B show an individual example record and trace of the
delayed response to pregabalin. These responses did
reverse but this took about 40 minutes with the response
developing 3–10 minutes after the start of pregabalin
application. No change in holding current or in the leak
conductances were associated with the long-term effect of
pregabalin and in the absence of pregabalin stable K+ cur-
rents were recorded from DRG neurones for 16 minutes
(n = 10).
Several pharmacological experimental approaches were
taken to characterise the biphasic actions of pregabalin
and to determine the possible mechanism of action
associated with the long-term K+  current modulation.
Apamin, a toxin from the honeybee, was used to block
small conductance Ca2+-activated K+ currents. Apamin (1
µM) caused a reduction in outward current at +40 mV
from 2.64 ± 0.33 nA to 2.37 ± 0.39 nA, subsequent appli-
cation of 250 µM pregabalin enhanced the current to 3.02
± 0.39 nA (n = 11; p<0.01). No inhibitory effects were seen
with pregabalin after treatment with apamin, suggesting
that it is the apamin-sensitive Ca2+-activated K+ channels
that are inhibited by pregabalin (Figure 12C &12D).
Gabapentin can be transported into cells via the L α-
amino acid transporter and may achieve intracellular con-
centrations 10–20 times the levels in the extracellular
environment [25]. Furthermore, actions through intracel-
lular signalling pathways and specifically protein kinase
A, have been proposed for gabapentin [12]. To examine
whether the long-term enhancement of K+ currents by pre-
gabalin might involve intracellular sites of action, we
applied pregabalin to the intracellular environments of
DRG neurones via the patch pipette solution. Intracellular
pregabalin (250 µM) evoked an increase in the K+ current
that started to develop within the first minute of entering
the whole cell recording configuration. After an initial
increase that could reflect equilibration with the KCl-
based patch pipette solution containing pregabalin, a
slow sustained significant increase in the outward K+ cur-
rent continued to develop over a 15 minute period (n =
10; p< 0.01; Figure 13A,13B). No similar change in K+ cur-
rent was observed in control studies carried out in the
absence of pregabalin (Figure 13C,13D).
Pertussis toxin pre-treatment results in the uncoupling of
sensitive G-proteins from effector mechanisms, including
voltage-activated Ca2+ and K+ channels. Additionally, per-
tussis toxin pre-treatment has previously been found to
influence gabapentin actions on ICa. Pertussis toxin pre-
treatment (500 ng/ml; 16–18 hours) prevented
pregabalin-induced long-term K+ current enhancement in
cultured DRG neurones (Figure 14A &14B).
The possible role of cAMP-dependent protein kinase A
(PKA) in the pregabalin-induced enhancement of K+ cur-
rent was then assessed using the inhibitor (Rp)-cAMP
[26]. Intracellular application of 30 µM (Rp)-cAMP
applied via the KCl-based patch pipette solution had no
effect over a 5 minute equilibration period on voltage-
activated K+ current (n = 9). This may indicate that PKA
has little or no basal or tonic activity on K+ currents in
DRG neurones in culture. However, when pregabalin was
applied to DRG neurones loaded with (Rp)-cAMP no
long-term enhancement of the outward current wasBMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
Page 16 of 26
(page number not for citation purposes)
Pregabalin modulates voltage-activated potassium currents in cultured DRG neurones Figure 10
Pregabalin modulates voltage-activated potassium currents in cultured DRG neurones. A) Traces showing that 2.5 µM pregab-
alin failed to significantly alter the outward K+ current evoked by a 100 ms voltage step command from -90 mV to 40 mV. B) 
Current / voltage relationship showing enhancement of outward current following 3 minutes application of 250 µM pregabalin 
(filled circles = control data and open circles currents recorded in the presence of pregabalin (PGB); * = P < 0.05 & ** = P < 
0.01). Inset traces show the control outward K+ current activated at +40 mV and the enhanced K+ current recorded in the 
presence of pregabalin (250 µM). C) Current / voltage relationship showing inhibition of outward K+ current following 3 min-
utes application of 250 µM pregabalin (filled circles = control data and open circles K+ currents recorded in the presence of 
pregabalin (PGB); * = P < 0.05). Inset traces show the control outward K+ current activated at +40 mV and the attenuated K+ 
current recorded in the presence of pregabalin (250 µM).
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Acute application of gabapentin produced modest inhibition of voltage-activated K+ currents in cultured DRG neurones but  long-term measurement of K+ currents shows a delayed enhancement in outward current Figure 11
Acute application of gabapentin produced modest inhibition of voltage-activated K+ currents in cultured DRG neurones but 
long-term measurement of K+ currents shows a delayed enhancement in outward current. A) Bar chart showing data for the 
acute (3–5 minutes) reversible inhibition of the mean K+ current by 250 µM gabapentin (GBP). B) Traces showing a control 
outward K+ current activated at 0 mV and the inhibited current activated at the same voltage after 3 minutes application of 250 
µM gabapentin (GBP). C) Traces showing the biphasic response to 250 µM gabapentin. Illustrated are the control current, the 
inhibited current recorded after 5 minutes application of gabapentin (GBP) and the enhanced outward current measured 5 
minutes after removal of the perfusion pipette containing gabapentin (Enhanced Current).
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Pregabalin produced delayed enhancement of K+ currents in cultured DRG neurones Figure 12
Pregabalin produced delayed enhancement of K+ currents in cultured DRG neurones. A) Line graph showing a time course for 
the delayed action of pregabalin in a single neurone, the open bar shows the period of application of pregabalin (250 µM). Little 
effect of pregabalin was seen in this neurone until 5 minutes after removal of the pressure ejection pipette containing pregaba-
lin. B) Inset traces show a control K+ current activated at +40 mV, modest enhancement of the K+ current after 5 minutes 
application of 250 µM pregabalin and the enhanced outward K+ current recorded 9 minutes after application of pregabalin. 
Apamin mimicked the inhibitory action of pregabalin on K+ current but did not prevent enhancement of the K+ current by 
acute application of 250 µM pregabalin. C) Bar chart showing the modest inhibitory effect of apamin (1 µM) on K+ current and 
the enhancement in K+ current when pregabalin was applied in the continued presence of apamin (Apamin & PGB). D) Traces 
showing a control K+ current, the inhibited K+ current in the presence of 1 µM apamin and the enhanced K+ current observed 
when apamin and pregabalin were applied together. Apamin prevented the inhibitory effect of pregabalin but not the enhance-
ment of K+ current.
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Intracellular application of pregabalin enhanced K+ currents in cultured DRG neurones Figure 13
Intracellular application of pregabalin enhanced K+ currents in cultured DRG neurones. For these experiments pregabalin was 
included in the KCl-based patch pipette solution at a concentration of 250 µM. A) Bar chart showing the mean amplitudes of 
the K+ current recorded immediately after entering the whole cell recording configuration (Initial IK) and the maximum out-
ward current recorded within 16 minutes of entering the whole cell recording configuration (Max IK). B) Traces of the first K+ 
current recorded using a patch pipette solution containing 250 µM pregabalin (Initial) and from the same cell the maximum 
outward K+ current recorded with intracellular pregabalin (Max). C) Bar chart showing control data recorded from neurones 
not exposed to pregabalin. Illustrated are the mean amplitudes of the K+ current recorded immediately after entering the 
whole cell recording configuration (Initial IK) and the maximum K+ outward current recorded within 16 minutes of entering the 
whole cell recording configuration (Max IK). D) Traces of the first K+ current recorded using the standard KCl-based patch 
pipette solution (Initial) and from the same cell the maximum outward current recorded under control conditions, within 16 
minutes of entering the whole cell recording configuration (Max).
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Pertussis toxin pre-treatment and intracellular (Rp)-cAMP prevented enhancement of K+ current by pregabalin Figure 14
Pertussis toxin pre-treatment and intracellular (Rp)-cAMP prevented enhancement of K+ current by pregabalin. A) Bar chart 
showing the mean amplitude of K+ current recorded from DRG neurones pre-treated with pertussis toxin for 16–18 hours 
with 500 ng/ml (PTX Control) and after application of 250 µM pregabalin (PTX PGB), long term, up to 15 minutes monitoring 
of the current. B) Traces showing outward K+ currents recorded from a DRG neurone pre-treated with pertussis toxin, prior 
to pregabalin application (PTX Control) and 10 minutes after application of 250 µM pregabalin. C) Bar chart showing mean 
data obtained from neurones containing (Rp)-cAMP (30 µM), which was applied to the intracellular environment via the patch 
pipette solution. Data shows the mean K+ current amplitude recorded 1 minute and 5 minutes after entering the whole cell 
recording configuration (1 min; 5 min), after 5 minutes application of 250 µM pregabalin (PGB) and 10 minutes after removal of 
the pressure ejection pipette containing pregabalin. D) Traces from a single experiment showing the outward K+ currents at 1 
and 5 minutes after entering the whole cell recording configuration and allowing entry of 30 µM (Rp)-cAMP in the DRG neu-
rones. Also shown are the K+ current inhibited by 5 minutes application of 250 µM pregabalin (PGB) and the recovery of the 
K+ current after the pressure ejection pipette containing pregabalin was removed. Intracellular (Rp)-cAMP prevented the 
delayed long-term enhancement of the K+ current evoked by pregabalin.
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observed. Under these recording conditions pregabalin
still produced some inhibition of the K+ current (Figure
14C &14D). These data provide evidence that the long-
term modulation of voltage-activated K+ channels by pre-
gabalin is dependent on PKA-mediated phosphorylation.
Conclusions
In conclusion, these results indicate that pregabalin acts
via the same basic mechanisms as gabapentin to inhibit
voltage-activated Ca2+ channels and that these inhibitory
actions are independent of GABA receptor activation.
Some features of the actions of pregabalin on intermedi-
ate size and large DRG neurones appear not to be seen
with gabapentin. However, these distinct responses
involve enhanced K+-evoked Ca2+ transients by pregabalin
rather than inhibition of Ca2+ channels.
Alpha2δ subunits of voltage-activated Ca2+  channels
remain a possible site of action for both pregabalin and
gabapentin. Dooley and colleagues showed that both
gabapentin and pregabalin attenuated K+-evoked nore-
pinephrine release from rat neocortical slices by
inhibiting P/Q-type Ca2+ channels [10]. In cortical pyram-
idal neurones gabapentin predominantly works through
L-type Ca2+ channels [27]. Our work with Bay K8644 indi-
cates that in cultured DRG neurones gabapentin [5] and
pregabalin act predominantly independently of L-type
channels. A recent study has also indicated that acting via
G-protein coupled GABAB  receptors, gabapentin selec-
tively inhibited N-type Ca2+ channels in hippocampal
pyramidal neurones [15]. Interestingly, this selectivity of
gabapentin seen in the hippocampus is different from the
Ca2+ channel modulation seen with the GABAB receptor
agonist, baclofen. Our previous investigation using "toxi-
typing" showed that gabapentin inhibited a variety of
Ca2+ channels in DRG neurones [11]. We conclude from
all this work that gabapentin and pregabalin may have
allosteric interactions with promiscuous α2δ Ca2+ channel
subunits. These α2δ subunits are not specifically com-
bined with distinct pore forming Ca2+ channel subunits
(α1) in all neurones and may therefore inhibit pharmaco-
logically diverse Ca2+ channels depending on the expres-
sion of Ca2+  channel subunits in different neurones.
However, transfection studies have shown that oocytes
expressing Ca2+ channels (Cav2.2) containing β1b and
α2δ-1 or α2δ-2 subunits are insensitive to acute
application of 50 µM gabapentin [28]. This work raises
the possibility that other mechanisms independent of α2δ
– Ca2+ channel subunits are involved in the modulation of
neuronal excitability by gabapentin. Additionally, the
modulation of voltage-activated Ca2+ channels by gabap-
entin and pregabalin acting through indirect mechanisms
has been suggested. Candidates for such indirect mecha-
nisms include the control of Ca2+  channel functional
expression [29,30] and metabotropic mechanisms linked
to pertussis toxin sensitivity and PKA activation [12].
In hippocampal pyramidal neurones, uncoupling G-pro-
teins from metabotropic receptors with N-ethylmaleimide
prevents modulation of K+ and Ca2+ channels by gabapen-
tin [15]. However, in DRG neurones it is not clear how
pertussis toxin influences the actions of gabapentin and
pregabalin but it may involve disruption of multi-protein
complexes of G-proteins and ion channel subunits after
ADP-ribosylation of Gα. The role of any G-protein cou-
pled receptors in either gabapentin or pregabalin
responses in DRG neurones are not supported by our
investigations with SCH-202676. Furthermore, receptor
and direct G-protein involvement in pregabalin effects on
Ca2+ channels also appears unlikely in DRG neurones.
This is because in this study we found that intracellular
flash photolysis of GTP-γ-S had no influence on pregaba-
lin-evoked current inhibition and pregabalin did not alter
responses to GTP-γ-S. Our findings are in agreement with
those made in a previous study on cells expressing
GABAB1a/B2 or GABAB1b/B2 receptor subunits. In this study
GABA and the GABAB receptor agonist baclofen evoked
[35S]-GTP-γ-S binding responses but even at high concen-
trations both gabapentin and pregabalin did not [31].
The experiments designed to assess potential roles of
GABA receptors in the responses to pregabalin showed
that GABA receptor desensitization or the blockade of
GABAB receptors did not attenuate pregabalin actions.
These findings add to the published studies that indicate
that gabapentin and pregabalin effects are independent of
GABA receptor activation at least in some preparations
[31,32]. Specifically, in cultured DRG neurones gabapen-
tin was previously found not to activate a Cl- conductance
to alter membrane potential and input resistance and the
GABAB receptor antagonist saclofen did not influence the
inhibitory action of gabapentin on ICa [12].
Pregabalin has a higher affinity for α2δ subunits than
gabapentin and in a number of studies is more effective.
When applied alone pregabalin produced enhancement
in Ca2+ flux in some neurones, an effect not seen with
gabapentin. So, it was surprising to see in the imaging
experiments that when gabapentin and pregabalin were
applied together they produced only inhibitory effects.
This may reflect the allosteric interactions between these
drugs and α2δ subunits of Ca2+ channels as well as indirect
modulation of Ca2+ dependent conductances and interac-
tions with components of cell signalling.
There appear to be some inconsistencies in the pregabalin
data when its actions on voltage-activated Ca2+ currents
are compared with effects on K+-evoked Ca2+ transients.
This may in part be due to effects of pregabalin on mem-BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
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brane conductances in addition to voltage-activated Ca2+
currents. These effects may not be detected under voltage
clamp recording conditions where Na+ and K+ currents are
blocked to isolate Ca2+ currents. In the imaging experi-
ments all voltage-activated conductances are intact and
may be modulated by pregabalin. Alternatively, pregaba-
lin could potentially have a direct or indirect influence on
Ca2+-induced Ca2+ release from intracellular stores and
alter Ca2+ homeostatic mechanisms. These effects may be
modulated differently in different sub-populations of
DRG neurones and so produce the mixed responses
recorded in small, intermediate and large neurones in this
study. Thus different actions of pregabalin may be
detected using fura-2 fluorescence imaging but these addi-
tional mechanisms may not influence the measurements
of Ca2+ currents. Although mixed responses to gabapentin
were not previously identified, neither were clear effects
on the amplitude of K+-evoked Ca2+ transients apparent in
DRG neurones [11], although they were seen in differen-
tiated F-11 cells [12]. These apparent anomalies seen with
pregabalin do not appear to be due to drug effects on
Ca2+-induced Ca2+ release or Ca2+ homeostatic mecha-
nisms such as Na+/Ca2+ exchange. This conclusion was
reached because pregabalin did not influence Ca2+ tran-
sients evoked by caffeine and still enhanced K+-evoked
Ca2+ transients in choline chloride-based (low Na+) extra-
cellular solution.
The mixed responses to pregabalin seen in the Ca2+ imag-
ing experiments prompted us to investigate the actions of
pregabalin on voltage-activated K+ currents, which could
be modulated to cause an increase in Ca2+ influx. This
speculation was supported by the finding that application
of the K+ channel inhibitor, TEA, enhanced K+-evoked
Ca2+ transients. Stefani and colleagues have reported inhi-
bition of outward K+ currents by gabapentin [18]. Addi-
tionally, in rat hippocampal and human neocortical brain
slices gabapentin has been shown to inhibit K+-evoked
[3H]-noradrenaline release. The activation of KATP chan-
nels is implicated in these responses because not only
does glibenclamide, a KATP channel antagonist, attenuate
the gabapentin response but also pinacidil, a KATP channel
agonist, mimics the response and did not have additive
effects with gabapentin [33].
Mixed or biphasic responses to gabapentin and pregaba-
lin were seen, with both inhibition and enhancement of
K+  currents observed. The inhibitory actions of both
gabapentin and pregabalin on K+ currents recorded from
DRG neurones may not reflect a direct action of these
drugs on K+ channels. The effects of apamin, which pre-
vented the inhibition of outward current by pregabalin
indicated that small conductance Ca2+-activated K+ chan-
nels were involved in the response. This is consistent with
the effects of gabapentin seen in isolated cortical neurones
[18]. The pregabalin inhibitory action on voltage-acti-
vated Ca2+ channels may underlie the inhibition of out-
ward K+ current. A reduction in Ca2+ influx would lead to
reduced activation of Ca2+-activated K+  channels and
therefore a smaller outward current. If this indirect effect
of pregabalin resulted in a disproportionate reduction in
Ca2+-activated K+ conductances this may result in pro-
longed depolarisation. In turn a prolonged depolarisation
may maintain activation of Ca2+ channels that are insensi-
tive to pregabalin and an increase in Ca2+ influx as seen in
a sub-population of larger DRG neurones in the Ca2+
imaging experiments. It is not clear why gabapentin,
which produced modest inhibition of K+ currents, did not
also produce enhancement of K+-evoked Ca2+ transients.
It may be explained by a balance between inhibition of
Ca2+ influx through voltage-activated channels and mod-
ulation of Ca2+ flux through inhibition of K+ conductance.
Consistent with this hypothesis, gabapentin appears to be
less effective than pregabalin at modulating K+-evoked
Ca2+ transients in DRG neurones. This is supported by our
previous study that showed that gabapentin did not sig-
nificantly alter the peak Ca2+ transients [11].
The delayed enhancement of voltage-activated K+ currents
by gabapentin and pregabalin is a powerful mechanism
for reducing cell excitability. The slow development of
this response and its gradual decline suggested that intra-
cellular signalling events were involved. Pregabalin pro-
duces enhancement of K+ currents when applied either
inside or outside DRG neurones. The delay in the
development of these responses is less with intracellular
application of pregabalin, suggesting that it may have an
intracellular site of action. This effect may also depend on
drug uptake into cells via L α-amino acid transporters and
the presence and activity of these transporters may greatly
influence cell sensitivity to gabapentin and pregabalin.
Although it is not clear how gabapentin and pregabalin
might activate PKA, it is a candidate target site. Our previ-
ous work showed that inhibition of Ca2+ currents by
gabapentin was sensitive to cAMP analogues that acti-
vated or inhibited PKA [12]. Similarly, in this present
study (Rp)-cAMP blocked enhancement of K+ currents by
pregabalin. In the literature there are a number of reports
of PKA altering neuronal excitability and modulating K+
conductances. PKA is involved in pain signalling, playing
a role in prostaglandin-induced activation and sensitiza-
tion of DRG neurones [34]. PKA activity attenuates KV3.2
channel currents [35] and A-type current [36] and is
involved in the inhibition of K+ conductances by prostag-
landin E-2 [37]. Our results are not explained by these
findings but PKA has also been implicated in presynaptic
inhibition of GABA release [38], large conductance cal-
cium – and voltage-activated K+ channel activity [39] and
cannabinoid receptor mediated modulation of ion chan-
nels [40]. In the context of our project, of particular inter-BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
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est is the biphasic modulation in retinal cones of voltage
dependent K+ and Ca2+ channels by a synthetic cannabi-
noid receptor agonist and the sensitivity of these
responses to Wiptide, a PKA inhibitor [40]. However, the
G-protein pharmacology is different in the cone cells sug-
gesting different PKA activation pathways in DRG neu-
rones exposed to pregabalin. There appears to be a
considerable number of apparently conflicting effects
mediated by PKA, although a number of different prepa-
rations have been studied. The concept of conditional
protein phosphorylation such that initial phosphoryla-
tion state affects the sensitivity of different effector targets
to subsequent activation [39] could determine responses
to gabapentin and pregabalin acting through PKA. A
future challenge will be to determine how PKA plays roles
in activation and sensitization of DRG neurones and also
plays a role in gabapentin and pregabalin responses to
dampen down electrical excitability in the same neurones.
Perhaps answers will come when we have a better under-
standing of the changes in neuronal phenotype that
develop with pain disorders?
An interesting feature of some actions of gabapentin and
pregabalin is that their effects often outlast the period of
drug delivery. Maintained intracellular signalling effects
of these drugs and the delayed responses involving PKA
modulation of Ca2+ and K+ conductances may underlie
this characteristic.
Gabapentin has previously been shown to attenuate high
frequency action potential firing both in CNS neurones
[41] and in cultured DRG neurones [5,12]. Pregabalin
produces the same effect, dramatically but reversibly
reducing the number of action potentials fired in response
to 300 ms depolarising current commands. The underly-
ing mechanisms involved in these reductions in electrical
excitability could involve inhibition of voltage-activated
Ca2+ channels with resulting reduced activation of Ca2+-
activated K+ currents and effects on voltage-dependent
ion channel availability. Although the delayed enhance-
ment of voltage-activated K+ channels could contribute,
this effect appears to develop over a longer period. These
actions may contribute both to anticonvulsant effects of
gabapentin and pregabalin as well as their therapeutic
actions in pain disorders. It is particularly worth noting
that the inhibition of Ca2+ influx is most consistently seen
in small diameter cultured DRG neurones that are likely
to be the pain fibres.
Our data adds to previous work that has assessed the
actions of gabapentin and pregabalin on K+-evoked neu-
rotransmitter release in CNS neurones [10] and the phar-
macology of pain in whole animal models [8,9,42-44].
The present work and these previous studies suggest that
gabapentin and pregabalin mostly act through the same
basic mechanisms. These mechanisms in cultured DRG
neurones appear to involve allosteric inhibitory modula-
tion of Ca2+ channels through drug interactions with α2δ
subunits, reduced activation of Ca2+-dependent conduct-
ances and modulation of both Ca2+  and K+  channels
through metabotropic mechanisms that involve PKA.
Interestingly, both gabapentin and pregabalin inhibit
release of sensory peptides (substance P and CGRP) this
may provide a mechanism of action down-stream of ion
channel modulation. This effect is only observed after
inflammation and may contribute to their analgesic prop-
erties of gabapentin and pregabalin [45].
Ca2+ channels in DRG neurones are targets for antinocice-
ptive agents but the pharmacology of these channels
remains to be fully exploited in pain therapy [46,47]. Fur-
ther studies on changes in ion channel subunit expression
and alterations in intracellular signalling pathways in
pain disorders may in the future open up new therapeutic
opportunities.
Methods
Cell culture
One to four-day old Sprague-Dawley rats were decapitated
and dorsal root ganglia removed. DRG neurones were
dissociated enzymatically (0.125% collagenase for 13
minutes and 0.25% trypsin for 6 minutes) and mechani-
cally (trituration). Primary cultures of DRG neurones were
plated on lamin-polyornithine coated coverslips and
bathed in Ham's F-14 culture medium (Imperial Labora-
tories) containing 10% horse serum (Gibco), low NGF
(20 ng/ml; Sigma), NaHCO3 (14 mM), streptomycin (50
µg/ml) and penicillin (50 IU/ml). The cultures were
maintained for up to two weeks at 37°C in humidified air
with 5% CO2. Cultures were re-fed with fresh media after
5 days.
In some experiments DRG neurones were pre-treated with
pertussis toxin (500 ng/ml; for 18 hours) to ADP-ribo-
sylate the α subunits of certain G-proteins. This prevents
pertussis toxin-sensitive G-protein being activated
through a range of G-protein coupled receptors and inhib-
its coupling to voltage-activated Ca2+ channels and other
potential effectors [12,48].
Electrophysiology and calcium imaging
The whole cell patch clamp recording method and fura-2
Ca2+ imaging were used to measure the inhibitory actions
of pregabalin and gabapentin on Ca2+ entry through volt-
age-activated channels. Initially, multiple firing properties
of a sub-population of DRG neurones were studied using
a patch pipette solution containing in mM: KCl, 140;
EGTA, 5; CaCl2, 0.1; MgCl2, 2.0; HEPES, 10.0; ATP, 2.0.
The extracellular solution containing in mM: NaCl, 130;
KCl, 3.0; CaCl2 2.0; MgCl2, 0.6; NaHCO3 1.0, HEPES 10.0BMC Pharmacology 2004, 4:14 http://www.biomedcentral.com/1471-2210/4/14
Page 24 of 26
(page number not for citation purposes)
and glucose 5.0. For recording Ca2+ channel currents the
patch pipettes were filled with CsCl-based solution con-
taining in mM: 140 CsCl, 0.1 CaCl2, 5 EGTA, 2 MgCl2, 2
ATP, 10 Hepes. The pH and osmolarity of the patch
pipette solutions were corrected to 7.2 and 310–320
mOsm.l-1 with Tris and sucrose. The extracellular bathing
solution used to study Ca2+ currents contained in mM:
130 choline chloride, 2 CaCl2, 3 KCl, 0.6 MgCl2, 1
NaHCO3, 10 HEPES, 5 glucose, 25 tetrethylammonium
chloride, 0.0025 tetrodotoxin (Sigma). The pH and osmo-
larity of this extracellular bathing solution was corrected
to 7.4 and 320 mOsml-1 with NaOH and sucrose respec-
tively. The recording solutions used in these experiments
were designed to attenuate voltage-activated Na+ and K+
currents and isolate voltage-activated Ca2+ currents. The
range of values for the series resistance under our record-
ing conditions was from ~8 to 15 MΩ. Pregabalin and
other drugs were applied to the extracellular environment
by low-pressure ejection from a blunt pipette positioned
about 50–100 µm away from the cell being recorded.
Voltage-activated Ca2+ currents were evoked by 100 ms
voltage step commands applied every 30 s.
Similar protocols were used to study the actions of prega-
balin on voltage-activated K+  currents but NaCl-based
extracellular bathing solution and KCl-based patch
pipette solutions were used.
In some experiments GTP-γ-S was photoreleased inside
DRG neurones. Caged GTP-γ-S (100 µM; Molecular
Probes) was included in the CsCl-based patch pipette
solution. After obtaining control Ca2+  currents
intracellular flash photolysis was achieved by flashing the
neurone being studied (three 200 V flashes to produce
~15µM GTP-γ-S) using a XF-10 xenon flash lamp with a
UG11 bandpass filter (Hi-Tech Scientific; [49])
All voltage-activated Ca2+ and K+ currents had scaled linear
leakage and capacitance currents subtracted to obtain
values for the net inward Ca2+ current or net outward K+
current. Data are given as mean ± standard error of the
mean (s.e.m.) values and statistical significance was deter-
mined using a paired or independent Student's t test as
appropriate.
For Ca2+ imaging in cultured DRG neurones the cultures
were incubated for 1 hour in NaCl-based extracellular
solution contained (in mM): NaCl, 130; KCl, 3.0; MgCl2,
0.6; CaCl2, 2.0; NaHCO3, 1.0; HEPES, 10.0; glucose, 5.0
and fura-2AM, 0.01; (Sigma, 1 mM stock in dimethylfor-
mamide). The pH was adjusted with NaOH to 7.4 and the
osmolarity to 310–320 mOsm with sucrose. The cells
were then washed for 10–20 minutes with NaCl-based
extracellular solution to remove the extracellular fura-
2AM and this period allowed cytoplasmic de-esterifica-
tion of the Ca2+ sensitive fluorescent dye. The cells were
constantly perfused with NaCl-based extracellular solu-
tion (1–2 ml/min) and viewed under an inverted
Olympus BX50WI microscope with a KAI-1001 S/N
5B7890-4201 Olympus camera attached. Some Ca2+
imaging experiments were carried out using a Ca2+-free
NaCl-based solution (as standard NaCl-based extracellu-
lar solution but with no added CaCl2) or choline chloride-
based solution (as standard NaCl-based extracellular solu-
tion but with choline chloride in place of NaCl). The flu-
orescence ratiometric images from data obtained at
excitation wavelengths of 340 nm and 380 nm were
viewed and analysed using OraCal pro, Merlin morphom-
etry temporal mode (Life Sciences resources, version
1.20). The DRG neurones were stimulated with NaCl-
based extracellular solution containing high K+ (30 mM),
which produced depolarisation, activation of voltage-
gated Ca2+ channels and large transient increases in intra-
cellular Ca2+. Three consistent transient increases in intra-
cellular Ca2+ could be obtained in a single experiment on
cultured DRG neurones [11]. The actions of pregabalin
and gabapentin (2.5–250 µM) were investigated on the
response to the second stimulus in DRG neurones. The
actions of pregabalin and gabapentin on the Ca2+ tran-
sient amplitude, duration at 1/2 peak amplitude and total
Ca2+ flux were measured. All experiments were conducted
at room temperature and data are expressed as means ±
s.e.m.
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